[EN] A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF [FR] COMPOSÉ UTILISÉ COMME AGONISTE DU RÉCEPTEUR BÊTA DES HORMONES THYROÏDIENNES ET SON UTILISATION
[EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2009020990A1
公开(公告)日:2009-02-12
Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
新型吡咯吡嘧啶如公式(I)所示,及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
Aluminium Chloride-Catalyzed Intermolecular<i>vs</i>Intramolecular Friedel-Crafts Reaction of Acrylanilides and 3-Chloropropanamides
3-Phenylpropionanilide (4a) is obtained in a yield of 89% from acrylanilide by the treatment with AlCl3/benzene, compared with a yield of 39% by the 1,4-conjugate addition of phenyllithium. The formation of 4a indicated that an intermolecular Friedel-Craftsreaction occurred, rather than the relatively more facile intramolecular ring cyclization, and provided a more efficient route than a conjugate
2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer
申请人:Chamberlain Stanley Dawes
公开号:US20100204196A1
公开(公告)日:2010-08-12
Novel pyrrolopyrimidines as shown in formula (I):
and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
式(I)所示的新型吡咯吡咪啉及其药学上可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
申请人:GlaxoSmithKline LLC
公开号:US07981903B2
公开(公告)日:2011-07-19
Novel pyrrolopyrimidines as shown in formula (I):
and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
式(I)所示的新型吡咯吡嗪化合物及其药学上可接受的衍生物。这些化合物可用于抑制IGF-1R。
Design, Synthesis, and Biological Evaluation of β-Trifluoroethoxydimethyl Selenides as Potent Antiosteoporosis Agents
An efficient protocol for the synthesis of β-trifluoroethoxydimethylselenides was achieved under mild reaction conditions, and 39 compounds were prepared. All compounds were evaluated for their abilities to inhibit RANKL-induced osteoclastogenesis, compound 4aa exhibited the most potent activity. Further investigations revealed that 4aa could inhibit F-actin ring generation, bone resorption, and osteoclast-specific